Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients

Fig. 1

Comparisons of plasma biomarkers between MCI who progressed to AD dementia and those who did not. Levels of plasma p-tau217 (A), NfL (B), Aβ42/Aβ40 ratio (C), and GFAP (D) between MCI patients who did not progress to AD dementia (non-progressors) vs. those who progressed to AD dementia (progressors) within 3 years. Boxes represent the first and third quartile of each distribution, and whiskers extend up to 1.5-times the interquartile range. Corresponding p-value and Cohen’s d effect size are reported on the top of each panel. Aβ, beta-amyloid; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; MCI, mild cognitive impairment; p-tau217, phosphorylated tau 217

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193